Wedbush Reiterates Outperform Rating for Unity Biotechnology (NASDAQ:UBX)

Unity Biotechnology (NASDAQ:UBX – Get Rating)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a report issued on Thursday, Benzinga reports. They currently have a $35.00 target price on the stock.

UBX has been the topic of a number of other reports. Mizuho lowered their price objective on shares of Unity Biotechnology from $80.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, November 16th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Unity Biotechnology in a research report on Wednesday, February 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $34.25.

Unity Biotechnology Stock Performance

Shares of UBX opened at $3.78 on Thursday. The company’s 50 day moving average price is $4.30 and its 200 day moving average price is $3.87. Unity Biotechnology has a 52 week low of $2.09 and a 52 week high of $18.50. The company has a market capitalization of $53.64 million, a PE ratio of -0.52 and a beta of 0.79. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.12 and a current ratio of 6.12.

Institutional Trading of Unity Biotechnology

Several large investors have recently modified their holdings of the company. ARCH Venture Management LLC bought a new stake in shares of Unity Biotechnology during the 3rd quarter worth $3,970,000. Vanguard Group Inc. raised its stake in Unity Biotechnology by 246.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,437,259 shares of the company’s stock valued at $1,753,000 after purchasing an additional 3,155,586 shares during the last quarter. Empery Asset Management LP acquired a new position in Unity Biotechnology during the 3rd quarter valued at $1,743,000. Altium Capital Management LP acquired a new position in Unity Biotechnology during the 3rd quarter valued at $1,687,000. Finally, 683 Capital Management LLC acquired a new position in Unity Biotechnology during the 3rd quarter valued at $1,115,000.

Unity Biotechnology Company Profile

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.